Phase 3's primary outcome was efficacy assessment on preventing mild, moderate and severe disease.[1] It was conducted on 20,000 participants[2] across 6 cities in Iran (Tehran, Karaj, Shiraz, Isfahan, Mashhad and Bushehr).[3] Phase III has been reached on April 21;[4] and the first injections occurred on April 25.[39] Up to June 14, 18,000 volunteers received their first dose and 2,000 received their second dose of the vaccine or placebo.[6] Dr. Minoo Mohraz was the first volunteer of the phase 3 that received the vaccine.[40]